Puregon was launched in Denmark, Germany and the UK for ovulation
induction in clomiphene-resistent anovulation and controlled ovarian
hyperstimulation. Transfected Chinese hamster ovary cells with plasmids containing
the genes encoding the α- and β-FSH subunits produced recFSH that was similar to
uroFSH. In both cases (follitropin α and β) no antibody formation was detected,
however, this form appeared to be more active than follitropin α in that there was a
25% greater pregnancy rate compared to uroFSH.
